RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study
RAK Medical and Health Sciences University
479 participants
Mar 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah. The main questions it aims to answer are: * Can a pharmacist-led education program reduce unnecessary PPI use? * Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes. Participants will: * Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan. * Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing. * Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.
Eligibility
Inclusion Criteria8
- Physicians will be eligible to participate if:
- They are prescribing PPIs in outpatient department of the study sites
- They have patients with potentially inappropriate PPI prescriptions
- Patients will be eligible to participate if:
- They are ≥18 years
- They are presenting to out-patient departments of the study sites
- They have prescriptions of potentially inappropriate PPIs
- Their treating physicians are included in the study
Exclusion Criteria5
- Physicians will be excluded if:
- • They are involved in any other prescribing trial
- Patients will be excluded if:
- They are unable to give informed consent, as judged by their physicians
- They have definitive indications for PPI use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions. At the end of the 6-month period, the educational materials provided to the intervention group will be offered to the control group.
Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06858384